Credit Suisse Maintains Neutral on CRISPR Therapeutics, Lowers Price Target to $65
Credit Suisse analyst Richard Law maintains CRISPR Therapeutics (NASDAQ:CRSP) with a Neutral and lowers the price target from $78 to $65.
Needham Maintains Buy on CRISPR Therapeutics, Lowers Price Target to $82
Needham analyst Gil Blum maintains CRISPR Therapeutics (NASDAQ:CRSP) with a Buy and lowers the price target from $122 to $82.
CRISPR Therapeutics Q4 EPS $(1.41) Beats $(2.30) Estimate, Sales $6.00K Miss $7.12M Estimate
CRISPR Therapeutics (NASDAQ:CRSP) reported quarterly losses of $(1.41) per share which beat the analyst consensus estimate of $(2.30) by 38.7 percent. This is a 23.37 percent increase over losses of $(1.84) per share
Analyst Initiates Coverage On This Peer Lagging Gene-Editing Stock
Cantor Fitzgerald initiated coverage on Editas Medicine Inc (NASDAQ:EDIT) with an Overweight rating and a price target of $15. The analyst says…
Jim Cramer Says This Is ‘One Of Those Crazy Science Stocks That In This Market Will Work Perfectly’
On CNBC’s "Mad Money Lightning Round," Jim Cramer said he really likes Qualtrics International Inc (NASDAQ: XM) as a
Cathie Wood Gets Elon Musk’s Attention Over Gene-Editing Therapy Potential: ‘Investors Chased The Dream Then. Now, They’re Running Away’
Cathie Wood of ARK Investment Management believes U.S. equity markets are the polar opposite of what they were in the 90s when investors chased their dreams.
What 5 Analyst Ratings Have To Say About CRISPR Therapeutics
CRISPR Therapeutics (NASDAQ:CRSP) has observed the following analyst ratings within the last quarter: Bullish Somewhat Bullish Indifferent Somewhat…
Citigroup Maintains Neutral on CRISPR Therapeutics, Lowers Price Target to $63
Citigroup analyst Yigal Nochomovitz maintains CRISPR Therapeutics (NASDAQ:CRSP) with a Neutral and lowers the price target from $83 to $63.